Clinical trials: Chorea, Huntington
Huntington's Disease
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT).
- Trial name
- ChANGE HD (NCT01860339)
- Where
- 6 sites in United States
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Peggy C Nopoulos
Parkinson's Disease, Parkinsonian Disorders
Gait Analysis in Neurological Disease
The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with…
- Conditions
- Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy
- Trial name
- NCT02994719
- Testing
- Anti-Parkinson medication, Deep Brain Stimulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Tardive Dyskinesia, Huntington Disease
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy…
- Trial name
- NCT06216054
- Testing
- LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Huntington Disease
Making HD Voices Heard
The Pilot Study, Making HD Voices Heard, will ask people living with HD to report what they experience and how they function.
- Trial name
- NCT05268029
- Where
- United States
- Volunteers
- 698 people
- Sponsor
- Huntington Study Group
Huntington Disease, Healthy
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
- Trial name
- MEND-HD (NCT07010705)
- Testing
- ActiGraph LEAP, Axivity AX6
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Huntington's Disease
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
- Trial name
- MermaiHD (NCT00665223)
- Testing
- ACR16
- Where
- 31 sites in Austria, Belgium and 6 more
- Volunteers
- 437 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Huntingtons Disease
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response…
- Trial name
- NCT04000594
- Testing
- RO7234292 (RG6042)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease, Huntington Disease
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
The underlying goal of this study is to assess [123I]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
- Trial name
- MNI-420 (NCT00970229)
- Testing
- [123I]MNI-420
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Rare Diseases
European Registry on Rare Neurological Diseases
The recent implementation of European Reference Networks for Rare Diseases (ERNs) is an unprecedented move to improve the care of patients suffering from rare health disorders by transnational collaboration.
- Trial name
- ERN-RND reg (NCT04319796)
- Testing
- Data set as defined by the ERN Research Workgroup of the European Commission
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Tuebingen
Huntington Disease
Nilotinib in Huntington's Disease
Based on strong pre-clinical evidence of the effects of Nilotinib on neurodegenerative pathologies, including autophagic clearance of neurotoxic proteins, neurotransmitters (dopamine and glutamate), immunity and behavior, the…
- Trial name
- Tasigna HD (NCT03764215)
- Testing
- Nilotinib 150 MG
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Georgetown University
Huntington Disease
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.
- Trial name
- NCT02907294
- Testing
- PBF-999 / 160 mg, PBF-999 / 320 mg
- Where
- Spain
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Neuromuscular Diseases, Obesity (Disorder)
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement.
- Conditions
- Neuromuscular Diseases, Obesity (Disorder), Myotonic Dystrophy 1, Myasthenic Syndrome
- Trial name
- Acti-Adult (NCT07136844)
- Testing
- Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT)
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Huntington's Disease
Cognitive Assessment Battery (CAB) Beta Study
The overall objective of this study is to identify a 60 minute cognitive battery, for subsequent use in clinical trials, that detects cognitive deficits in early HD and late pre-manifest HD compared to controls, and that has a…
- Trial name
- CAB (NCT01290861)
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Huntington's Disease
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
- Trial name
- NCT01806896
- Testing
- PF-02545920
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Pfizer
Frontotemporal Dementia, Huntington Disease
Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)
Behavioural disorders are very common right from the initial stage of dementia and contribute to loss of autonomy. Behavioural dysexecutive disorders have a particular status due to their prevalence and their diagnostic…
- Conditions
- Frontotemporal Dementia, Huntington Disease, Alzheimer Disease, Semantic Dementia
- Trial name
- ISDC (NCT02819700)
- Testing
- prevalence of behavioural dysexecutive syndrome
- Where
- 2 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Huntington Disease
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of…
- Trial name
- NCT07516899
- Testing
- [14C] LPM3770164
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Huntington Disease
Long Term Follow-up Grafted Huntington's Disease Patients
Long-term follow-up of Huntington's disease patients treated with intrastriatal allografts is essential to assess the benefit/risk ratio of grafts as well as their effectiveness.
- Trial name
- Post-MIGHD (NCT06194006)
- Testing
- Follow-up
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington's Disease
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers
- Trial name
- NCT02208934
- Testing
- PBF-999
- Where
- 2 sites in Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Huntington's Disease
Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease
This study will examine whether lithium carbonate, given alone or with divalproex, increases the amount of brain-derived neurotrophic factor (BDNF) in the spinal fluid of patients with Huntington's disease (HD), a hereditary…
- Trial name
- NCT00095355
- Testing
- Lithium, Divalproex
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Huntington's Disease
Exercise Effects in Huntington's Disease
Huntington's disease (HD) is an incurable and fatal disorder characterised by progressive degeneration of the basal ganglia and the cerebral cortex.
- Trial name
- NCT01879267
- Testing
- Exercise training
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich